July 10th 2025
Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.
Viral Load Decline Achieved Faster in Pregnant Women Treated with Raltegravir
March 5th 2019A trial comparing raltegravir with efavirenz for antiretroviral therapy in treatment naïve pregnant women with HIV supports the use of raltegravir, especially for women starting ART later in gestation.
Read More
Ending the HIV Epidemic in the US: Why Now Is the Right Time
March 5th 2019Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, has been fighting HIV/AIDS since the 1980s when the virus was first discovered. Now, thanks to a joint effort by multiple arms of the US Department of Health and Human Services, he’s making headway.
Read More
IMPAACT Study on HIV Medications Taken During Pregnancy to Begin New Phase in 2019
February 5th 2019In an ongoing study spanning more than 15 years, investigators have made key discoveries about how HIV and TB drugs affect pregnant and postpartum women, leading to new safety and dosing recommendations for several medications.
Read More
When Access Is Not an Issue, Perception of Risk Drives PrEP Uptake
January 31st 2019Patients who believe themselves to be at a high risk of contracting HIV are more likely to accept pre-exposure prophylaxis (PrEP) than their peers. That’s one key finding from a new study that looked at how individual factors affect PrEP uptake.
Read More